Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
Receive an email update when we add a new PULMONARY FIBROSIS article.
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- Danazol Treatment for Telomere Diseases on February 18, 2019 at 5:10 pm
Genetic defects in telomere maintenance and repair cause bone marrow failure, liver cirrhosis, and pulmonary fibrosis, and they increase susceptibility to cancer. Historically, androgens have been use... […]
- Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis on February 18, 2019 at 10:52 am
The mRSS is a clinically validated and FDA-accepted endpoint measuring the evolution of skin fibrosis ... is an FDA-accepted endpoint measuring pulmonary function, overall progression of the ... […]
- Woman spending 'life-changing' wait on transplant list on February 17, 2019 at 5:34 pm
“I was ignoring it,” Dawn Burke said. Then came two bouts of pneumonia, one month apart. Tests led to a stunning diagnosis: Idiopathic Pulmonary Fibrosis (IPF), a disease that scars the lungs for unkn... […]
- Kleinert, Diane Marie on February 16, 2019 at 12:30 pm
MADISON / SUN CITY, Ariz. - Diane Marie Kleinert (Nachreiner) passed away Jan. 21, 2019, with her family by her side from complications of Parkinson's Disease, Pulmonary Fibrosis and Pneumonia. Diane ... […]
- Sande C. Whalen on February 16, 2019 at 10:26 am
Whalen, Sande C. Age 68, of Columbia Heights passed away peacefully after a battle with Pulmonary Fibrosis on February 1, 2019. She will be fondly remembered for her love of her family. She enjoyed pl... […]
- Latest Report Examines Global Idiopathic Pulmonary Fibrosis Market : Driving Force & Growth Factors | Merck, Cipla on February 15, 2019 at 3:32 pm
Qyresearchreports include new market research report "Global Idiopathic Pulmonary Fibrosis Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. The market for Idiopa... […]
- Allergic Bronchopulmonary Aspergillosis on February 14, 2019 at 7:38 am
If unrecognized or poorly treated, ABPA leads to airway destruction, bronchiectasis and/or pulmonary fibrosis, resulting in significant morbidity and mortality. The clinician should note that the deve... […]
- lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p on February 12, 2019 at 4:13 am
Long non-coding RNAs (lncRNAs) have been reported to be involved in various pathophysiological processes in many diseases. However, the role and mechanism of lncRNAs in pulmonary fibrosis have not bee... […]
- Autophagic flux blockage in alveolar epithelial cells is essential in silica nanoparticle-induced pulmonary fibrosis on February 12, 2019 at 3:45 am
Silica nanoparticles (SiNPs) have been reported to induce pulmonary fibrosis (PF) with an unknown mechanism. Recently, the activation of autophagy, a lysosome-dependent cell degradation pathway, by Si... […]
via Bing News